Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.

Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin Cancer Res. 2005 Jun 1; 11(11):4151-9.

View in: PubMed